Cardiol Therapeutics Inc. CRDL

CRDL Company Overview

Cardiol Therapeutics Inc. is a Canada-based clinical-stage biotechnology company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The company operates within the biopharmaceutical and cardiovascular therapeutics industries, with a strategic emphasis on inflammatory cardiac conditions that currently have limited approved treatment options. Its primary product candidate portfolio includes proprietary pharmaceutical cannabidiol formulations designed for conditions such as recurrent pericarditis, myocarditis, and heart failure. The company’s revenue generation has historically been limited because it remains in the clinical development stage and has not commercialized approved therapies as of publicly available filings through 2025.

The company’s lead clinical asset is CardiolRx™, an orally administered cannabidiol formulation under investigation for inflammatory heart disease indications. Cardiol Therapeutics has also advanced subcutaneous drug delivery initiatives through its CRD-38 program. The company positions itself around pharmaceutical-grade cannabidiol manufacturing standards, intellectual property development, and targeted cardiovascular applications, distinguishing itself from broader cannabinoid-focused companies that operate in consumer wellness or recreational markets. Founded in 2017, the company evolved from early-stage cannabinoid pharmaceutical development into a specialized cardiovascular therapeutics developer listed on both the Nasdaq Capital Market and the Toronto Stock Exchange.